BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
-10.49%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$720M
AUM Growth
+$720M
(-9.9%)
Cap. Flow
+$6.32M
Cap. Flow
% of AUM
0.88%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
$6.3M |
| 2 |
Lineage Cell Therapeutics
LCTX
|
$24.1K |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 47.47% |
| 2 | Consumer Staples | 37.71% |
| 3 | Industrials | 5.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
STAAR Surgical
STAA
$1.36B
| $279M | 38.8% | 10,840,630 | – | – |
|
2
Monster Beverage
MNST
$60.9B
| $272M | 37.71% | 4,679,308 | – | – |
|
3
iShares Russell 2000 ETF
IWM
$67B
| $63.6M | 8.82% | 420,000 | – | – |
|
4
Axon Enterprise
AXON
$58.7B
| $43.2M | 5.99% | 760,062 | – | – |
|
|
5
Lineage Cell Therapeutics
LCTX
$267M
| $33.3M | 4.63% | 34,005,379 +24,553 | +0.1% | +$24.1K |
|
|
IMDX
6
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $23.3M | 3.24% | 11,098,267 +3,000,000 | +37% | +$6.3M |
|
7
Serina Therapeutics
SER
$54.5M
| $5.87M | 0.82% | 2,997,156 | – | – |
|